Video

Predictive Value of Diagnostic Tests

Bryan Loy, MD, describes how diagnostic test results can be of help to providers when having conversations with their patients about treatments. Providing patients with a more specific concept of response and recurrence, such as percentages or odds, can help patients understand their options.

Related Videos
Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS
Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS
Cathy Eng, MD, FACP, FASCO
Elevating Cancer Care Through Personalized Treatment
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
How Do Infusion Pharmacies Support Financial Sustainability in Oncology?
Screenshot of an interview with Shaun McKenzie, MD
Identifying Good Candidates for Histotripsy to Treat Liver Tumors
Screenshot of an interview with Shaun McKenzie, MD
Histotripsy May Expand Beyond Liver Tumors, but Long-Term Data Are Still Needed
Screenshot of an interview with Rohan Garje, MD
Barriers That Prevent Access to Optimal Treatment in Primary Urethral Cancer
Susan Escudier, MD, FACP
The Need for Payer Support in Overcoming Cancer Care Disparities
Sabarish Ayyappan, MD
Geographic Barriers Impede Access to Novel Cancer Treatments
Fueling Cancer Research Breakthroughs With Patient Contributions
Fueling Cancer Research Breakthroughs With Patient Contributions
Susan Escudier, MD, FACP
Addressing Financial Toxicity and Clinical Trial Disparities in Community Oncology
Related Content
AJMC
April 4th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

Galen Shearn-Nance, BS Rishi R. Sachdev, BS Long Vu, MS Weichuan Dong, PhD Alberto J. Montero, MD, MBA Siran M. Koroukian, PhD Johnie Rose, MD, PhD
This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw
The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Doctor showing patient x-ray of lung cancer. | Image credit: Nattakorn – stock.adobe.com
March 25th 2025

3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

Hayden E. Klein
One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.
Estrogen | Image credit: Debalina - stock.adobe.com
March 20th 2025

Estrogen Therapy May Increase Risk of 3 Skin Cancers

Hayden E. Klein
Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo